In line with our findings in EOC, very recent data have proposed a role for SFPQ in prostate cancer, where it promotes the expression of the androgen receptor variant 7, associated with castration resistance [32], supporting a role for SFPQ in promoting cancer-specific progression and resistance to therapy via the regulation of the alternative splicing. The gene discussed is SFPQ; the disease is prostate carcinoma.